= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.Nebivolol Development and Commercialization Agreement • May 30th, 2008 • Forest Laboratories Inc • Pharmaceutical preparations • New York
Explanatory Note: This Agreement was amended by the Amendment Agreement between the Parties dated as of February 27, 2008 (the "2008 Amendment"), a copy of which is being filed with the Securities and Exchange Commission simultaneous with the filing of this Agreement. Accordingly, this Agreement includes notations to direct readers to the 2008 Amendment with respect to those sections which were revised by the 2008 Amendment and has been conformed to reflect the deletion of those sections which were removed by the 2008 Amendment.
= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.Nebivolol Development and Commercialization Agreement • May 30th, 2008 • Forest Laboratories Inc • Pharmaceutical preparations
AMENDMENT AGREEMENT (this "Amendment Agreement") dated as of February 27, 2008 (the "Amendment Effective Date") by and between FOREST LABORATORIES HOLDINGS LIMITED, an Irish corporation having offices at Milner House, 18 Parliament Street, Hamilton HM 11, Bermuda ("Forest") and MYLAN INC. (formerly known as MYLAN LABORATORIES INC.), a Pennsylvania corporation having offices at 1500 Corporate Drive, Suite 400, Canonsburg, Pennsylvania 15317, on behalf of itself and its subsidiaries (collectively, "Mylan") to that certain NEBIVOLOL DEVELOPMENT AND COMMERCIALIZATION AGREEMENT dated as of January 6, 2006, as amended by letter agreements dated January 6, 2006 and January 11, 2006 (collectively, the "Agreement") by and between Forest and Mylan.
